Canada's Crescita Q4 revenue falls on prior-year one-time reimbursement
Overview
Canada dermatology firm's Q4 revenue fell yr/yr due to prior-year one-time reimbursement
Gross profit and margin rose, helped by higher-margin skincare sales and lower promotional costs
Company to be acquired by ClinActiv Holdings in all-cash deal at 74% premium, pending approvals
Outlook
Crescita expects acquisition by ClinActiv Holdings to close in Q2 2026
Company says economic uncertainty and softness in skincare market continue to impact operations
Crescita remains focused on operational execution while awaiting acquisition approvals
Result Drivers
PRIOR-YEAR ONE-TIME REIMBURSEMENT - Q4 revenue decline mainly due to $1.62 mln inventory reimbursement in Q4-2024 after amending agreement with largest manufacturing client
SKINCARE AND E-COMMERCE SALES - Higher Q4 skincare revenue, primarily from increased e-commerce sales and incremental revenue from Bacti Control acquisition, partly offset revenue decline
HIGHER OPERATING COSTS - Q4 operating expenses rose mainly due to increased advertising and promotion for digital sales, and higher regulatory, consulting and distribution fees
Company press release: ID:nBwT8Ll4a
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue |
| C$5.96 mln |
|
Q4 Adjusted EBITDA |
| C$70,000 |
|
Q4 Gross Margin |
| 54.40% |
|
Q4 Operating Expenses |
| C$3.62 mln |
|
Q4 Operating Income |
| -C$381,000 |
|
Q4 Pretax Profit |
| -C$702,000 |
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
